http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-190580-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13 |
| filingDate | 1997-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f737221b8e0246ad0e28cc47eff11098 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e7651c8cc8541b35549dfaaab956408 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35cabe56c60415366f3dcb997e459cb6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1015b043f40f90de313372754ec992d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc6e1de21d37f219281348977e41731b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a628e5038ea54482a934fb13919688c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f78ba1d6401e5ac48616951b08bec327 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c47afe557555adcda18a87146db078d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_329ff63155a9b8ba65b4b92c661e944a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cf5b5ddacef26960561f52d5d1a88a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_720a6082e879acf3db4dad1510226cf6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_470b0af359b58577bd80943e42368343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2afd9534b341b44b4f8fa48c00fcdf3 |
| publicationDate | 2005-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PL-190580-B1 |
| titleOfInvention | New derivatives of 1,7,7-trimethylbicyclo [2.2.1] heptane, the method of their preparation, pharmaceutical compositions and the use of new derivatives |
| abstract | 1. A compound of formula (I) and a pharmaceutically acceptable addition salt thereof with an inorganic or organic acid. 4. A process for the preparation of a compound of formula (I) as defined in claim L and a pharmaceutically acceptable acid salt thereof, characterized in that it comprises: a) monodemethylation of a compound of formula (II) by reacting it with a compound of general formula (IV) in which R 1 is a C 1-4 alkyl group, a phenyl group or a naphthyl group and Hlg is a halogen, and subjecting the compound of general formula (V), wherein R1 is as defined above, to react with a base, or b) removal by catalytic hydrogenation of the benzyl protecting group from the compound of formula (V) general formula (III) wherein R is benzyl; and, if desired, separating the resulting racemic compound (I) into optically active isomers, preferably by fractional crystallization or by applying a chromatographic separation, preferably using a chiral column, and, if desired, converting the compound of formula (I) into a pharmaceutically acceptable acid addition salt or liberation of the base from its salt. 8. A pharmaceutical composition containing inert solid or liquid carriers or auxiliaries, characterized in that the active ingredient is a compound of formula (I) or a pharmaceutically acceptable addition salt thereof with an inorganic or organic acid. Template I PL PL PL |
| priorityDate | 1996-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.